Your browser doesn't support javascript.
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Hideaki Kato; Yutaro Yamaoka; Hirofumi Go; Takeharu Yamanaka; Akihide Ryo.
  • Kei Miyakawa; Department of Microbiology, Yokohama City University School of Medicine
  • Sundararaj Stanleyraj Jeremiah; Department of Microbiology, Yokohama City University School of Medicine
  • Hideaki Kato; Infection Prevention and Control Department, Yokohama City University Hospital
  • Yutaro Yamaoka; Department of Microbiology, Yokohama City University School of Medicine
  • Hirofumi Go; Department of Biostatistics, Yokohama City University Graduate School of Medicine
  • Takeharu Yamanaka; Department of Biostatistics, Yokohama City University Graduate School of Medicine
  • Akihide Ryo; Department of Microbiology, Yokohama City University School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-21256788
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Qualitative research Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Qualitative research Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint